Prenatal ultrafine particle (UFP; <0.1 µm) exposure is associated with asthma development in children.
In patients with refractory eosinophilic asthma, treatment with benralizumab is a cost-effective option to be used as add-on therapy.
There was a substantial decrease in asthma exacerbations among Black and Hispanic patients during the COVID-19 pandemic.
Patients who have severe eosinophilic asthma that is uncontrolled on omalizumab may be effectively switched to mepolizumab.
Patients with severe uncontrolled asthma receiving tezepelumab experienced fewer exacerbations, better lung function, and quality of life improvements compared with placebo.